| Name | Title | Contact Details |
|---|
Multimatic Inc. is a Canadian company founded in 1984 and based in Markham, Ontario. It specializes in providing automotive components, systems, complete vehicles, and engineering services on a global scale. With manufacturing and engineering facilities across North America, Europe, and Asia-Pacific, Multimatic has evolved from producing basic automotive parts to offering advanced vehicle dynamics and niche vehicle production. The company operates through several divisions, including Multimatic Mechanisms, which manufactures hinge systems and powered closures, and Multimatic Structures & Suspension, known for structural components and advanced suspension systems. Multimatic Engineering supports product development and manufacturing, while the Niche Vehicles division focuses on low-volume, high-performance sports cars. Additionally, Multimatic Motorsports designs and builds race cars, contributing to the companys engineering advancements. Multimatic collaborates with major automotive brands such as Ford, Honda, Volkswagen, and Aston Martin, providing innovative solutions and expertise in the automotive industry.
The RAMPF Group stands for engineering and chemical solutions and caters to the economic and ecological needs of industry. Our range of competences includes: 🧪 Production and recycling of materials for modeling, lightweight construction, bonding, and protection ⚙️ Technical production systems for precise, dynamic positioning and automation, as well as technologies for complex composite parts production 💡 Comprehensive range of solutions and services, particularly for innovative customer-specific requirements Please find our imprint here: https://www.rampf-group.com/de/impressum/ https://www.rampf-group.com/en/imprint/
ParetoHealth is a healthcare benefits solutions provider focused on midsize employers with 50 to 1,000 employees. The company aims to reduce healthcare cost volatility and improve financial outcomes through innovative self-insurance models. It has established itself as the largest health benefits captive in the U.S., managing over $6.6 billion in healthcare spending and serving more than 3,000 employers, which collectively cover over 1 million lives. The company offers a range of services, including its Risk Shield program, which provides a shared-risk model for predictable costs and stop-loss protection against large claims. Its Savings Engine utilizes data analytics and clinical expertise to manage medical costs and improve pharmacy solutions through the ParetoHealth Pharmacy Consortium. By pooling employers into a single risk pool, ParetoHealth enhances negotiating leverage and risk stabilization, allowing midsize businesses access to cost-saving tools typically available to larger corporations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.